Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers report.